SCHEMBL8946

SCHEMBL8946

O=c1c(-c2cccc(F)c2)c(CNc2ncnc3[nH]cnc23)oc2ccc(F)cc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 10/20 0.49
PIK3CG P48736 3/20 0.49
MAP4K4 O95819 4/20 0.39
AURKA O14965 3/20 0.39
AURKB Q96GD4 3/20 0.39
CLK4 Q9HAZ1 2/20 0.39
DAPK3 O43293 1/20 0.39
JAK2 O60674 1/20 0.39
PRKD3 O94806 1/20 0.39
PAK4 O96013 1/20 0.39
ABL1 P00519 1/20 0.39
LCK P06239 1/20 0.39
CSF1R P07333 1/20 0.39
RET P07949 1/20 0.39
PDGFRB P09619 1/20 0.39
FGFR1 P11362 1/20 0.39
PRKACA P17612 1/20 0.39
FLT1 P17948 1/20 0.39
LTK P29376 1/20 0.39
GRK5 P34947 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30670789 1.00 PIK3CD (0.49) PIK3CDPIK3CGMAP4K4AURKAAURKB
SCHEMBL30670914 0.95 PIK3CD (0.55) PIK3CDPIK3CGMAP4K4AURKAAURKB
SCHEMBL8975 0.95 PIK3CD (0.55) PIK3CDPIK3CGMAP4K4AURKAAURKB
SCHEMBL30670869 0.94 PIK3CD (0.44) PIK3CDPIK3CGMAP4K4AURKAAURKB
SCHEMBL8721 0.94 PIK3CD (0.44) PIK3CDPIK3CGMAP4K4AURKAAURKB
SCHEMBL15688348 0.91 PIK3CD (0.47) PIK3CDPIK3CGMAP4K4AURKAAURKB
SCHEMBL8573 0.86 PIK3CD (0.54) PIK3CDPIK3CGMAP4K4MAPK14GABRP
SCHEMBL16783465 0.85 PIK3CD (0.45) PIK3CDPIK3CGMAP4K4AURKAAURKB
SCHEMBL8546 0.84 PIK3CD (0.43) PIK3CDPIK3CGAURKAMAPK14MEN1
SCHEMBL16395748 0.84 PIK3CD (0.53) PIK3CDPIK3CGMAP4K4MAPK14GABRP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4292596-A1 METHOD AND COMBINATION FOR TREATING TUMORS Curon Biopharmaceutical (Shanghai) Co., Limited (CN) 2023-12-20 EP claimed
CN-117222413-A Methods and combinations for treating tumors 同润生物医药(上海)有限公司 2023-12-12 CN claimed
WO-2022171121-A1 METHOD AND COMBINATION FOR TREATING TUMORS 同润生物医药(上海)有限公司 2022-08-18 WO claimed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 US claimed
EP-2496567-B1 NOVEL BENZOPYRAN KINASE MODULATORS RHIZEN PHARMACEUTICALS S A (CH) 2017-07-12 EP claimed
US-20160318890-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2016-11-03 US claimed
US-9421209-B2 Kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2016-08-23 US claimed
US-20150174131-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2015-06-25 US claimed
US-9018375-B2 Substituted chromenes as kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2015-04-28 US claimed
US-20140080827-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2014-03-20 US claimed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 US claimed
EP-2496567-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2012-09-12 EP claimed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US claimed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US claimed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 WO claimed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 US disclosed
US-20240139198-A1 METHOD AND COMBINATION FOR TREATING TUMORS CURON BIOPHARMACEUTICAL (SHANGHAI) CO., LIMITED (CN) 2024-05-02 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150174131-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CG 99/4885MAP4K4 195/4885
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CG 99/4885MAP4K4 195/4885
US-20140080827-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CG 99/4885MAP4K4 195/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CG 99/4885MAP4K4 195/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CG 99/4885MAP4K4 195/4885
US-20160318890-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CG 99/4885MAP4K4 195/4885
US-20240139198-A1 METHOD AND COMBINATION FOR TREATING TUMORS PDCD1, PDCD1LG2, CD274 PIK3CD 116/4885PIK3CG 221/4885MAP4K4 1108/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CG 99/4885MAP4K4 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.